Formulation Development
Abzena Strengthens Executive Leadership Team With The Appointment of Taylor Boyd as CBO
Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today that Taylor Boyd has joined the company as its…
Veranova Relocates Headquarters to Devens, MA
Veranova is pleased to announce the move of its corporate headquarters to its Devens, Massachusetts facility, one of the company’s principal sites for manufacturing and…
Traws Pharma Reports Positive Results From an Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory…
Lexicon Pharmaceuticals Announces Topline Results From Phase 2b Study Evaluating Pilavapadin in Adults With Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals, Inc. recently announced topline results from the PROGRESS Phase 2b study evaluating pilavapadin (LX9211), an oral, non-opioid investigational adaptor-associated kinase 1 (AAK1) inhibitor…
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
Revive Therapeutics Ltd. recently announce that it has entered into a non-binding letter of intent (the “LOI”), dated February 28, 2025, to acquire the full…
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central…
WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide
Excipient variability plays a critical role in pharmaceutical product design. A risk-based, scientific approach to Quality by Design (QbD) is essential to ensure consistent drug…
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
Neurona Therapeutics recently announced plans to initiate the Phase 3 EPIC clinical trial for its lead product candidate, NRTX-1001. NRTX-1001 is the first investigational human cell…
Phoenix Molecular Designs Dosed First Patient in Dauntless-1, a Phase 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer
Phoenix Molecular Designs recently announced the dosing of the first patient in their Phase 2 clinical trial, Dauntless-1. The Dauntless-1 trial will evaluate the therapeutic potential…
Tiziana Life Sciences Announces Agreement for Product Development Services With Renaissance Lakewood
Tiziana Life Sciences, Ltd. recently announced a product development services agreement with Renaissance Lakewood LLC, a leading Contract Development and Manufacturing Organization (CDMO) focused on…
Medigene AG Expands Patent Portfolio With Patent Grant for its JOVI Technology in the US
Medigene AG recently announced it has been issued a patent by the US Patent Office protecting its JOVI technology, a method allowing the enrichment of…
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
IMUNON, Inc. recently announced new translational data from ongoing analyses of results from the Company’s Phase 2 OVATION 2 Study of IMNN-001, its investigational interleukin-12 (IL-12)…
Atrandi Biosciences Raises $25M Series A Led by Lux Capital to Drive the Future of Single-Cell Multiomics with Semi-Permeable Capsule Technology
Atrandi Biosciences recently announced a $25 million Series A funding round led by Lux Capital, with participation from Vsquared Ventures, Practica Capital, Metaplanet and GRIDS Capital.…
Silo Pharma Expands Intellectual Property Portfolio With Provisional Patent
Silo Pharma, Inc. recently announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15.…
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex
Artelo Biosciences, Inc. recently announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). The findings were presented by Professor Saoirse…
IN8bio Presents Positive Phase 1 Data Highlighting Durability of Remissions in High-Risk AML
IN8bio, Inc. recently presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy (TCT) Meetings in…
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Bicara Therapeutics Inc. recently announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab…
Abcuro Announces $200 Million Financing to Advance its First-In-Class Medicine in Development for Inclusion Body Myositis
Abcuro, Inc. recently announced the closing of a $200-million Series C financing led by New Enterprise Associates (NEA) with Foresite Capital joining the round and…
Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology
Mangoceuticals, Inc. recenntly announced it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian…
MediWound Initiates the VALUE Global Phase 3 Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers
MediWound Ltd. recently announced the initiation of VALUE, a global, pivotal Phase 3 trial evaluating EscharEx for the treatment of venous leg ulcers (VLUs). “We…
